102 results
6-K
EX-99.2
VALN
Valneva SE
26 Mar 24
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
6:44am
(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the
the safety … marketing authorization in Europe. Phase 1 results from Valneva’s first-generation Zika vaccine candidate were reported in 2018 showing a favorable safety
6-K
EX-99.1
VALN
Valneva SE
20 Mar 24
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
12:52pm
years.
A clinical study in adolescents, VLA1553-321, is ongoing in Brazil, for which Valneva reported initial safety data in August 202316. Funded … were observed20,21,22. These include the announcement in September 2023 of positive Phase 2 pediatric and adolescent immunogenicity and safety data
6-K
EX-99.1
m11r3
10 Jan 24
Current report (foreign)
12:42pm
6-K
EX-99.1
oghf91d0u 1v6585f0l0
5 Dec 23
Current report (foreign)
8:50am
6-K
EX-99.2
tj69ln088a42zs12d8y
5 Dec 23
Current report (foreign)
8:50am
6-K
EX-99.1
jvh f07jt7nvacx
13 Nov 23
Current report (foreign)
6:10am
6-K
EX-99.2
e1mquqlyofcc2qv7h
13 Nov 23
Current report (foreign)
6:10am
6-K
EX-99.1
zq18np9x e12z
9 Nov 23
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
10:40am
6-K
EX-99.1
per47z6huf3kwiepxf72
27 Oct 23
Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment
5:00pm
6-K
EX-99.1
jkgybsl8w1w9od
13 Oct 23
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
5:00pm
6-K
EX-99.1
0bkv q9zd
21 Sep 23
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
10:52am
6-K
EX-99.2
2l8b 97xh
21 Sep 23
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
10:52am
6-K
EX-99.1
grtfpvxg
7 Sep 23
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
5:00pm
6-K
EX-99.2
i0mmspm3 lgg
29 Aug 23
Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
8:00am
6-K
EX-99.1
mk31k6rdgihw33i2
29 Aug 23
Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
8:00am
6-K
EX-99.1
55kba1n1
14 Jun 23
Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet
12:00pm
6-K
EX-1
d7h63sl 9g44fa16v
4 May 23
Current report (foreign)
11:38am